Potassium Lowering Therapies Hit NICE Hurdle In UK

 
• By Eleanor Malone

AstraZeneca’s Lokelma and Vifor’s Veltassa will be subject to a final review by the England and Wales health technology appraisal body in December following draft guidance not recommending their use in the National Health Service to treat hyperkalemia.

Roadblock
AZ and Vifor hope to move NICE roadblock • Source: Shutterstock

More from Health Technology Assessment

More from Market Access